Stryker reported a higher profit and revenue growth in the second quarter as the company recovers from a March cyberattack.

The medical technology company on Thursday reported a profit of $1.28 billion, or $3.30 a share, compared with a profit of $884 million, or $2.29 a share, a year earlier.

Stripping out certain one-time items, Stryker posted adjusted earnings of $3.69 a share. Analysts surveyed by FactSet were expecting $3.49 a share.

Sales rose to $6.59 billion from $6.02 billion, beating analyst expectations for $6.58 billion. MedSurg and Neurotechnology sales rose 9.7%, while the orthopaedics unit reported 9.1% sales growth.

Stryker also narrowed its full-year guidance, projecting adjusted earnings of between $14.95 and $15.10 a share, up from a previous low end of $14.90. It expects organic net sales growth between 8.3% and 9.3%, compared with a previous range of 8% to 9.5%.

Analysts are expecting full-year adjusted earnings of $14.97 a share.

The new sales guidance includes a "modestly positive pricing impact," the company said.

Shares of Stryker fell 9.5% to $315.00 in after-hours trading on Thrusday.

Chief Executive Kevin Lobo said that company has made "significant progress in our recovery" from the March cyberattack, which disrupted Stryker's Microsoft systems and impacted its first-quarter results. The Wall Street Journal has reported that the hackers behind the attack said they were retaliating against the U.S. on Iran's behalf.

"As we have seen in the past, the resilience of our teams when faced with challenges was once again on display," Lobo said. "With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech."